Navigation Links
VLST Corporation Announces Board and Executive Management Appointments
Date:2/13/2008

- Dr. David L. Urdal, Dendreon Corporation, Joins Board of Directors, Ron

Myers Appointed Vice President Legal Affairs -

SEATTLE, Feb. 13 /PRNewswire/ -- VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, today announced the appointments of Dr. David L. Urdal, chief scientific officer of Dendreon Corporation (Nasdaq: DNDN), to the Company's board of directors and Mr. Ron Myers, former associate general counsel, intellectual property for Corixa Corp., as vice president, legal affairs and intellectual property.

"The addition of these talented and experienced professionals to VLST's board and management comes at a time of continued advancement and growth for our Company," said Martin Simonetti, president and chief executive officer of VLST. "Both Dave and Ron will be instrumental in helping to guide our efforts as we begin advancing our novel product candidates into the clinic."

"I am pleased to be joining VLST's board and to be working again with VLST cofounder, Dr. Craig Smith. We worked together at Immunex," said Urdal. "Craig's seminal work in the discovery of Enbrel is the basis for VLST's novel drug discovery platform."

Dr. Urdal has served as Dendreon's chief scientific officer since 1995. Prior to joining Dendreon, he held various positions with Immunex Corporation, including president of Immunex Manufacturing Corporation, vice president and director of development, and head of the departments of biochemistry and membrane biochemistry. At Immunex, Dr. Urdal participated in the discovery, development and commercialization of hematopoietic growth factors, cytokines and cytokine receptors, such as GM-CSF (Leukine(R)) and TNF-receptor (Enbrel(R)). Dr. Urdal has served as a director of Dendreon since 1995 and also serves as director for Ore Pharmaceuticals, Inc. Dr. Urdal received his M.S. in Public Health and his Ph.D. in Biochemical Oncology from the University of Washington.

Mr. Myers has broad experience in M&A, licensing, litigation and intellectual property, including more than 16 years experience in intellectual property acquisition, enforcement and defense in the biotech and pharmaceutical fields. Mr. Myers joined Corixa in 2004 and served as associate general counsel, intellectual property. In 2005, Corixa was acquired by GlaxoSmithKline, plc., during which time Mr. Myers played a key role in the transition of assets. Mr. Myers also served as senior patent counsel to Pfizer Inc., where his responsibilities included global management of Pfizer's antiviral therapeutic portfolio, as well as patent enforcement and defense in the US, Canada, Asia and Japan. Prior to his in-house work, Mr. Myers served as outside counsel to several Fortune 500 companies. Mr. Myers received an M.S. in Molecular Pharmacology from Thomas Jefferson University in Philadelphia, PA and his J.D. from George Washington University in Washington, DC.

VLST recently relocated its operations within Seattle to a new corporate headquarters at 307 Westlake Avenue North. The new office location provides for expanded laboratory and research facilities.

About VLST

VLST Corporation is a privately held biotechnology company dedicated to the streamlined discovery and development of novel therapeutics for the treatment of inflammatory and autoimmune disorders. The VLST approach combines novel bioinformatics and cutting-edge proteomics to provide a rapid and rational approach to identifying new targets for the development of novel biologic therapies. The VLST discovery platform has primary applications for the treatment of rheumatoid arthritis, Crohn's disease, multiple sclerosis, lupus and diabetes. For more information, please visit http://www.vlstcorp.com.

Contact:

Julie Rathbun

Rathbun Communications, Inc.

julie@rathbuncomm.com

(206) 769-9219


'/>"/>
SOURCE VLST Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
2. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
3. LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern
4. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
5. Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy
6. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
7. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
8. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
9. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
10. DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call
11. Baxa Corporation Launches New Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , Jan. 20, 2017 Bioptix, ... the "Company"), announced that on January 14, 2017 the ... under which the Company will terminate certain employees associated ... Diagnostics, Inc.  The Company commenced terminations on January 16, ... 30 days.  The Company may pay severance benefits in ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... PUNE, India , Jan. 19, 2017  Market Research Future ... The Global Market for Liquid Biopsy is growing rapidly and expected ... period. Market Highlights ... The Global Liquid Biopsy Market has been assessed as ... high growth figures and boom in the coming future. There has ...
Breaking Biology Technology:
(Date:12/16/2016)... 2016 The global wearable medical device market, in terms ... from USD 5.31 billion in 2016, at a CAGR of 18.0% ... ... advancements in medical devices, launch of a growing number of smartphone-based ... among healthcare providers, and increasing focus on physical fitness. ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... , Dec. 15, 2016 Advancements ... experience, health wellness and wellbeing (HWW), and ... in three new passenger vehicles begin to ... gesture recognition, heart beat monitoring, brain wave ... facial monitoring, and pulse detection. These will ...
Breaking Biology News(10 mins):